UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
FORM 8-K CURRENT REPORT
Pursuant to Section 13 or 15(d) of the |
Date of Report: April 26, 2006
(Date of earliest event reported)
Vicor Corporation
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction
of incorporation)
0-18277
(Commission File Number)
04-2742817
(IRS Employer
Identification Number)
25 Frontage Road, Andover, Massachusetts
(Address of principal executive offices)
01810
(Zip Code)
(978) 470-2900
(Registrant's telephone number, including area code)
Not Applicable
(Former Name or Former Address, if changed since last report)
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers On April 21, 2006, our Board of Directors appointed Joseph W. Kelly as a member of the Board of Directors of Vicor Corporation (the "Company") and a member of the Audit Committee of the Board of Directors starting on May 15, 2006 to serve until the 2006 annual meeting of stockholders and his successor is elected and qualified or until his earlier death, resignation or removal. The Board has determined that Mr. Kelly satisfies the requirements for independence set forth in Marketplace Rule 4200(a)(15) of the NASDAQ's listing standards. Since the beginning of the Company's last fiscal year, there was no transaction or series of similar transactions, nor is there any currently proposed transaction or series of similar transactions, to which the Company or any of its subsidiaries was or is to be a party, in which the amount involved exceeds $60,000 and in which Mr. Kelly, or members of his immediate family, had or will have a direct or indirect material interest.
Item 9.01. Financial Statements and Exhibits
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: April 26, 2006 |
VICOR CORPORATION
By: /s/ Mark A. Glazer |
|
|
Exhibit No. | Description |
99.1 | Press Release of Vicor Corporation dated April 26, 2006 |
ANDOVER, MA -- 04/26/2006 -- Vicor Corporation (NASDAQ: VICR) announced today the appointment of Joseph W. Kelly to its Board of Directors and Audit Committee effective as of May 15, 2006. Mr. Kelly currently serves as General Partner of Shanghai Venture Partners, a private investment firm and as Chief Financial Officer of Ivrea Pharmaceuticals, Inc., a venture capital financed company developing dermatological products. Mr. Kelly was previously Senior Vice President and Chief Financial Officer of Cytyc Corporation (NASDAQ: CYTC) and was a partner with Deloitte & Touche LLP.
"We are pleased to have Joe bring to our board the perspective of his business expertise," stated Patrizio Vinciarelli, Chairman and Chief Executive Officer.
Mr. Kelly, 61, formed Shanghai Venture Partners in 2001 and joined Ivrea Pharmaceuticals on a part-time basis at incorporation in 2005. In addition to Vicor, Mr. Kelly is a director of The Whalen Company, a privately held company engaged in the manufacture of heat exchangers. From 1995 through 2000, Mr. Kelly served Cytyc as both CFO and as Vice President of International. Earlier, Mr. Kelly was Chairman, CEO and CFO of Crop Genetics International, a publicly held agricultural biotechnology company. For seventeen years Mr. Kelly served Deloitte Haskins & Sells (now Deloitte & Touche LLP) in Europe and the USA. Mr. Kelly holds a bachelor's degree in business administration with an accounting major from Niagara University and is a certified public accountant.
Vicor Corporation designs, develops, manufactures and markets modular power components and complete power systems based upon a portfolio of patented technologies. Headquartered in Andover, Massachusetts, Vicor sells its products primarily to the communications, information technology, industrial control and military electronics markets.
For further information contact: Mark A. Glazer Chief Financial Officer Vicor Corporation Tel: 978-470-2900 Fax: 978-749-3439